These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30946085)

  • 41. Indistinguishable T2/T3-N0 rectal cancer on rectal magnetic resonance imaging: comparison of surgery-first and neoadjuvant chemoradiation therapy-first strategies.
    Kim JG; Song KD; Cha DI; Kim HC; Yu JI
    Int J Colorectal Dis; 2018 Oct; 33(10):1359-1366. PubMed ID: 30003363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonoperative Management or 'Watch and Wait' for Rectal Cancer with Complete Clinical Response After Neoadjuvant Chemoradiotherapy: A Critical Appraisal.
    Sammour T; Price BA; Krause KJ; Chang GJ
    Ann Surg Oncol; 2017 Jul; 24(7):1904-1915. PubMed ID: 28324284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant Chemoradiotherapy and Tumor Recurrence in Patients with Early T-Stage Cancer of the Lower Rectum.
    Hayes IP; Milanzi E; Gibbs P; Reece JC
    Ann Surg Oncol; 2020 May; 27(5):1570-1579. PubMed ID: 31773520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study.
    Li J; Liu H; Yin J; Liu S; Hu J; Du F; Yuan J; Lv B; Fan J; Leng S; Zhang X
    Oncotarget; 2015 Dec; 6(39):42354-61. PubMed ID: 26472284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility study of a Response Surveillance Program in locally advanced mid and low rectal cancer to increase organ preservation.
    Boubaddi M; Fleming C; Vendrely V; Frulio N; Salut C; Rullier E; Denost Q
    Eur J Surg Oncol; 2023 Jan; 49(1):237-243. PubMed ID: 36114048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
    Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonoperative management after neoadjuvant therapy for rectal cancer: A single institution experience over 5 years.
    Strode M; Shah R; Boland PM; Francescutti VA; Mangieri CW; Attwood K; Nurkin SJ
    Surg Oncol; 2019 Mar; 28():116-120. PubMed ID: 30851884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [An initial exploration of the application of transanal endoscopic microsurgery in rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy].
    Xue XQ; Zhou JL; Lin GL; Bai XS; Xiao Y; Wu B; Qiu HZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):560-565. PubMed ID: 31238635
    [No Abstract]   [Full Text] [Related]  

  • 49. Long-term outcomes of real world 'watch and wait' data for rectal cancer after neoadjuvant chemoradiotherapy.
    Simpson G; Hopley P; Wilson J; Day N; Haworth A; Montazeri A; Smith D; Titu L; Anderson J; Agbamu D; Walsh C
    Colorectal Dis; 2020 Nov; 22(11):1568-1576. PubMed ID: 32686268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Local excision after neoadjuvant chemoradiation therapy in advanced rectal cancer: a national multicenter analysis.
    Yu CS; Yun HR; Shin EJ; Lee KY; Kim NK; Lim SB; Oh ST; Kang SB; Choi WJ; Lee WY;
    Am J Surg; 2013 Oct; 206(4):482-7. PubMed ID: 23849272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conditional Probability of Survival After Neoadjuvant Chemoradiation and Proctectomy for Rectal Cancer: What Matters and When.
    Karagkounis G; Liska D; Kalady MF
    Dis Colon Rectum; 2019 Jan; 62(1):33-39. PubMed ID: 30451761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].
    Gu J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):507-513. PubMed ID: 31238630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application of imaging diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy].
    Zhang XY; Lu QY; Sun YS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):243-247. PubMed ID: 32192302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Guiding significance of pathological diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy].
    Li ZW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):248-251. PubMed ID: 32192303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis.
    Chadi SA; Malcomson L; Ensor J; Riley RD; Vaccaro CA; Rossi GL; Daniels IR; Smart NJ; Osborne ME; Beets GL; Maas M; Bitterman DS; Du K; Gollins S; Sun Myint A; Smith FM; Saunders MP; Scott N; O'Dwyer ST; de Castro Araujo RO; Valadao M; Lopes A; Hsiao CW; Lai CL; Smith RK; Paulson EC; Appelt A; Jakobsen A; Wexner SD; Habr-Gama A; Sao Julião G; Perez R; Renehan AG
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):825-836. PubMed ID: 30318451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers.
    Lavryk OA; Manilich E; Valente MA; Miriam A; Gorgun E; Kalady MF; Shawki S; Delaney CP; Steele SR
    Int J Colorectal Dis; 2020 Jan; 35(1):77-84. PubMed ID: 31776698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whether the watch-and-wait strategy has application value for rectal cancer with clinical complete response after neoadjuvant chemoradiotherapy? A network meta-analysis.
    Du R; Chang Y; Zhang J; Cheng Y; Li Y; Zhang C; Zhang J; Xu L; Liu Y
    Asian J Surg; 2024 Feb; 47(2):853-863. PubMed ID: 38042663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surgery may not benefit patients with locally advanced rectal cancer who achieved clinical complete response following neoadjuvant chemoradiotherapy.
    Han Z; Li M; Chen J; Ji D; Zhan T; Peng Y; Xue W; Li Y; Cai Y; Sun Y; Wu Q; Du C; Gu J
    Asian J Surg; 2022 Jan; 45(1):97-104. PubMed ID: 33888366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncological Outcomes and Hospital Costs of the Treatment in Patients With Rectal Cancer: Watch-and-Wait Policy and Standard Surgical Treatment.
    Hupkens BJP; Breukink SO; Stoot JHMB; Toebes RE; van der Sande ME; Melenhorst J; Beets GL; Dirksen CD
    Dis Colon Rectum; 2020 May; 63(5):598-605. PubMed ID: 32032202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.